ARTICLE | Finance

AsclepiX aims for basket of retinal indications with $35M series A

Perceptive Xontogeny Venture Fund invested alongside Perceptive Advisors’ master life sciences fund

June 24, 2020 10:56 AM UTC

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology.

Spun out of The Johns Hopkins University, the Baltimore start-up believes the round will be enough to generate safety and efficacy data for AXT107, which has a dual mechanism that targets VEGF and Tie2 to treat diabetic macular edema, wet age-related macular degeneration, and macular edema secondary to retinal vein occlusion. Three Phase I/IIa trials are to start this year...